Robert D Murray

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/828150/publications.pdf

Version: 2024-02-01

361413 345221 1,368 57 20 citations h-index papers

g-index 63 63 63 1763 docs citations times ranked citing authors all docs

36

#	Article	IF	CITATIONS
1	ChAdOx1 SARSâ€CoVâ€2 vaccination: A putative precipitant of adrenal crises. Clinical Endocrinology, 2023, 99, 470-473.	2.4	12
2	Outcomes of 756 patients with differentiated thyroid cancer and excellent response to treatment: An evidenceâ€based paradigm for longâ€ŧerm surveillance strategies. Clinical Endocrinology, 2022, 96, 395-401.	2.4	4
3	Adjuvant Rituximab—Exploratory Trial in Young People With Graves Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 743-754.	3.6	15
4	Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis. European Journal of Endocrinology, 2022, 186, 83-93.	3.7	7
5	Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors. Endocrine Reviews, 2022, 43, 794-823.	20.1	20
6	The severity of obstructive sleep apnoea does not influence ambient IGF†levels. Clinical Endocrinology, 2021, 94, 434-442.	2.4	0
7	Interpretation of the endocrinology of hospital inpatients. British Journal of Hospital Medicine (London, England: 2005), 2021, 82, 1-12.	0.5	0
8	Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults). Pituitary, 2021, 24, 622-629.	2.9	0
9	Characterization of patients with adrenal insufficiency and frequent adrenal crises. European Journal of Endocrinology, 2021, 184, 761-771.	3.7	16
10	Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Diabetes and Endocrinology,the, 2021, 9, 622-637.	11.4	29
11	Outcomes of Patients with Nelson's Syndrome after Primary Treatment: A Multicenter Study from 13 UK Pituitary Centers. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1527-1537.	3.6	26
12	Is Chemotherapy Implicated in the Development of Hypopituitarism in Childhood Cancer Survivors?. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1897-e1900.	3.6	5
13	Construction of a predictive scoring system as a guide to screening and confirmation of the diagnosis of primary aldosteronism. Clinical Endocrinology, 2020, 92, 196-205.	2.4	11
14	Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope < sup > \hat{A} \circ < sup >): data from the PATRO Adults study. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882094337.	3.2	6
15	Management of persistent acromegaly following primary therapy: The current landscape in the UK. Endocrinology, Diabetes and Metabolism, 2020, 3, e00158.	2.4	3
16	Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs. Expert Opinion on Drug Safety, 2020, 19, 1539-1548.	2.4	11
17	Current Management and Outcome of Pregnancies in Women With Adrenal Insufficiency: Experience from a Multicenter Survey. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2853-e2863.	3.6	30
18	Performance of the unilateral AV/IVC index in primary hyperaldosteronism subtype prediction: A validation study in a single tertiary centre. Clinical Endocrinology, 2020, 93, 111-118.	2.4	6

#	Article	IF	CITATIONS
19	Maternal dysglycaemia, changes in the infant's epigenome modified with a diet and physical activity intervention in pregnancy: Secondary analysis of a randomised control trial. PLoS Medicine, 2020, 17, e1003229.	8.4	60
20	Prothrombotic fibrin network characteristics in patients with acromegaly: a novel mechanism for vascular complications. European Journal of Endocrinology, 2020, 182, 511-521.	3.7	0
21	Title is missing!. , 2020, 17, e1003229.		0
22	Title is missing!. , 2020, 17, e1003229.		0
23	Title is missing!. , 2020, 17, e1003229.		0
24	Title is missing!. , 2020, 17, e1003229.		0
25	Title is missing!. , 2020, 17, e1003229.		0
26	Title is missing!. , 2020, 17, e1003229.		0
27	In Epigenomic Studies, Including Cell-Type Adjustments in Regression Models Can Introduce Multicollinearity, Resulting in Apparent Reversal of Direction of Association. Frontiers in Genetics, 2019, 10, 816.	2.3	20
28	Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study. Thyroid, 2019, 29, 1003-1011.	4.5	72
29	Hypothalamicâ€pituitary axis irradiation dose thresholds for the development of hypopituitarism in adultâ€onset gliomas. Clinical Endocrinology, 2019, 91, 131-140.	2.4	19
30	No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope $\hat{A}^{@}$): data from an observational, longitudinal study. BMC Endocrine Disorders, 2019, 19, 138.	2.2	9
31	Glucocorticoid management of adrenal insufficiency in the United Kingdom: assessment using real-world data. Endocrine Connections, 2019, 8, 20-31.	1.9	16
32	Mortality data from the European Adrenal Insufficiency Registryâ€"Patient characterization and associations. Clinical Endocrinology, 2018, 89, 30-35.	2.4	55
33	Management of glucocorticoids following adrenalectomy for <scp>ACTH</scp> â€independent Cushing's syndrome. Clinical Endocrinology, 2018, 89, 719-720.	2.4	2
34	Mortality data from the European Adrenal Insufficiency Registryâ€"Patient characterization and associations. , 2018, 89, 30.		1
35	ANRIL Promoter DNA Methylation: A Perinatal Marker for Later Adiposity. EBioMedicine, 2017, 19, 60-72.	6.1	65
36	Impaired quality of life in patients with treated acromegaly despite longâ€ŧerm biochemically stable disease: Results from a 5â€years prospective study. Clinical Endocrinology, 2017, 86, 806-815.	2.4	44

#	Article	IF	CITATIONS
37	Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency. Endocrine Connections, 2017, 6, 1-8.	1.9	53
38	Late-onset X-linked adrenal hypoplasia (DAX-1, NROB1): two new adult-onset cases from a single center. Pituitary, 2017, 20, 585-593.	2.9	30
39	Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity - data from the EU-AIR. Clinical Endocrinology, 2017, 86, 340-346.	2.4	45
40	In Response to: Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely than Other Glucocorticoids. journal of applied laboratory medicine, The, 2017, 1, 753-755.	1.3	1
41	Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity – data from the EU-AIR. , 2017, 86, 340.		1
42	Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour. Endocrinology, Diabetes and Metabolism Case Reports, 2017, 2017, .	0.5	8
43	DNA methylation at birth within the promoter of ANRIL predicts markers of cardiovascular risk at 9Âyears. Clinical Epigenetics, 2016, 8, 90.	4.1	49
44	Pituitary dysfunction following cranial radiotherapy for adultâ€onset nonpituitary brain tumours. Clinical Endocrinology, 2016, 84, 372-379.	2.4	61
45	The effects of pituitary and thyroid disorders on haemostasis: potential clinical implications. Clinical Endocrinology, 2016, 84, 473-484.	2.4	15
46	A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4189-4194.	3.6	27
47	The diagnosis and management of inpatient hyponatraemia and SIADH. European Journal of Clinical Investigation, 2015, 45, 888-894.	3.4	74
48	Endocrine sequelae beyond 10Âyears in survivors of medulloblastoma. Clinical Endocrinology, 2015, 83, 663-670.	2.4	29
49	The Early Life Origins of Cardiovascular Disease. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	5
50	The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure. European Journal of Endocrinology, 2015, 173, 583-593.	3.7	13
51	Lanreotide autogel in acromegaly – a decade on. Expert Opinion on Pharmacotherapy, 2014, 15, 2681-2692.	1.8	10
52	European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy. BMC Endocrine Disorders, 2014, 14, 40.	2.2	25
53	Atypical Presentation of RiedelÂ's Thyroiditis: Multifocal Nodular Fibrosis and Resolution with Levothyroxine. European Thyroid Journal, 2012, 1, 259-63.	2.4	1
54	A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2957-2968.	3.6	192

#	Article	IF	CITATIONS
55	The Diagnosis of Partial Growth Hormone Deficiency in Adults with a Putative Insult to the Hypothalamo-Pituitary Axis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1705-1709.	3.6	23
56	The Phenotype of Adults with Partial Growth Hormone Deficiency. Hormone Research in Paediatrics, 2005, 64, 12-17.	1.8	7
57	Central and peripheral actions of somatostatin on the growth hormone–IGF-I axis. Journal of Clinical Investigation, 2004, 114, 349-356.	8.2	132